IGIB team partially reverses a rare disease

Chetana and Aswini-Optimized

Two small, drug-like molecules can partially reverse some defects in zebrafish, say Chetana Sachidanandan (left) and Aswini Babu..

Researchers at IGIB have demonstrated that zebrafish can be used an animal model to study Rubinstein Taybi Syndrome (RSTS) in humans. They were able to partially reverse the disorder using a tiny portion of the Ep300a protein, and also by using two small molecules.

Researchers at Delhi’s Institute of Genomics & Integrative Biology (CSIR-IGIB) have for the first time used zebra fish to model the rare genetic disorder — Rubinstein Taybi Syndrome (RSTS) — seen in humans. They have also used two small molecules to partially reverse some of the defects caused by the disorder in zebrafish, thus showing them to be an ideal animal model for screening drug candidates. There is currently no cure or treatment for the disorder.

The Rubinstein Taybi Syndrome has a frequency of about one in one lakh people, and causes intellectual disability, growth retardation (short stature), craniofacial deformities, heart defects and broad thumbs and toes. The results were published in the journal Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease.

Since zebrafish genome has very close similarity to human genome and the embryonic developmental is very similar in the two, the team led by Dr. Chetana Sachidanandan at IGIB went about ascertaining that EP300, one of the two genes that cause the disorder is present in the fish and if mutations in this gene result in a RSTS-like disease in fish.

Using chemicals, the researchers inhibited the activity of the protein Ep300 to see if this resulted in the manifestation of the disorder in the brain, heart, face and pectoral fins (equivalent to forearm in humans). “Like in the case of humans, the same organs were affected in the fish when the functioning of the protein was stopped. This helped in confirming that the protein in question does the same functions in fish and humans,” she says.

Conserved from fish to humans

Since zebrafish commonly has two copies of many human genes, the researchers first verified if one or both the genes were functional and equivalent to the human gene that causes the disorder. “We found Ep300a gene was active and functional while Ep300b was not,” says Prof. Tapas K. Kundu from the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru and the other corresponding author. The Ep300a gene is responsible for producing a protein (Ep300) that opens up the DNA.

“The protein Ep300 is evolutionarily conserved from fish to humans. Though the Ep300 gene has been earlier identified in fish, its function was not known,” says Prof. Kundu.

Reconfirming the findings

Like in the case of fish treated with chemicals manifesting the disorder, fish mutants that lacked the Ep300a gene too exhibited defects very similar to those seen in humans. “When we introduced excess amount of a tiny portion of the Ep300a protein in the mutants, the craniofacial deformities became less severe [mutants had severed craniofacial deformities] and pectoral fins in the fish became normal,” she says.

But neuronal defects were not reversed, even partially. “It might be because only a portion of the protein was put into the fish. Probably, that potion isn’t sufficient to compensate for the loss of the whole protein,” Dr. Sachidanandan explains.

“It’s proof-of-concept that just a piece of the protein is sufficient to reverse some defects even if only partially in zebrafish,” Dr. Sachidanandan says.

Drug-like molecules

Alternatively, the researchers used two small molecules to reverse the defects. If the protein Ep300 is responsible for opening the DNA, there are other proteins that are responsible for closing the DNA. The two molecules were found from a screen of compounds well known for their ability to inhibit proteins responsible for closing the DNA.

Like in the case when excess amount of Ep300 protein was introduced, both the molecules could partially restore facial defects but not the neuronal defects.

“Introducing excess amount of a portion of the ep300 protein showed greater rescue of deformities than the small molecules,” says Aswini Babu from IGIB and first author of the paper. “But rescuing the deformities using small molecules is a relatively easier and better option.”

More studies are needed to discover ways to reverse the neuronal defects.

Published in The Hindu on February 10, 2018


One thought on “IGIB team partially reverses a rare disease

Comments are closed.